Business
Aethlon Medical Appoints Medical Device and Biomedical Executive, Nicolas Gikakis, to its Board of Directors
SAN DIEGO, July 6, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and
About this update from Aethlon Medical, Inc.
[{"type":"text","content":"SAN DIEGO, July 6, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced the appointment of Nicolas Gikakis to its Board of Directors (Board), effective July 3, 2023. Mr. Gikakis will also serve as a member of the Nominating and Corporate Governance Committee of the Board. In connection with the appointment of Mr. Gikakis as a director, the authorized size of Aethlon Medical's Board was increased to six members.\n\"Nick is a seasoned, global medical device and biomedical industry executive with over 20 years' experience including high-profile positions,\" stated Charles J. Fisher, Jr. M.D., Chief Executive Officer of Aethlon Medical. \"I am pleased to welcome Nick to our Board of Directors and look forward to leveraging his extensive experience and relationships as we continue to pursue the research and clinical development of the Hemopurifier®, a therapeutic blood filtration system that can bind and remove harmful exosomes and life-threatening viruses from blood and our investigation of its utility in the organ transplant market.\"\n\"The potential of the Hemopurifier within oncology and as a potential treatment for life-threatening diseases, as well as the organ transplant market is vast and I am excited to join the Board at such an important stage for the company,\" stated Mr. Gikakis. \"I look forward to working with my fellow directors and the entire Aethlon leadership team as we strive to position the company for long-term growth and value creation.\"\nFrom 2021 to May 2023, Mr. Gikakis served as the Head of Commercial for WearOptimo Pty Ltd, a private Australian medical device and digital health company. Previously, from 2017 to 2019, Mr. Gikakis was Vice President of Strategy and Corporate Development at Oventus Medical Limited, a private medical device company, during which time he assisted with the commercial expansion of its sleep apnea device. From 2012 to 2021, Mr. Gikakis held various leadership and independent strategic advisor positions in the healthcare industry in sales, marketing, product development, and corporate development and transactions, including for companies working with blood filtration and purification.\nMr. Gikakis earned a BS in bioengineering from the Univer...